ClinicalTrials.gov
ClinicalTrials.gov Menu

Study With a Topical Gel to Treat Common Warts in Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00117871
Recruitment Status : Completed
First Posted : July 11, 2005
Last Update Posted : February 19, 2007
Sponsor:
Information provided by:
Graceway Pharmaceuticals, LLC

Brief Summary:

The primary purpose of this study is to evaluate the effectiveness in adults of 2 different strengths of resiquimod gel applied to common wart(s) five times a week for up to 12 weeks.

A second purpose is to evaluate the safety of the drug.


Condition or disease Intervention/treatment Phase
Warts Drug: Resiquimod Phase 2

Study Type : Interventional  (Clinical Trial)
Enrollment : 48 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: A Two-Stage, Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 5 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Adults
Study Start Date : October 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Warts
U.S. FDA Resources




Primary Outcome Measures :
  1. Clearance of treated wart(s)

Secondary Outcome Measures :
  1. Partial clearance of treated wart(s)


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of common warts
  • Two forms of birth control

Exclusion Criteria:

  • Pregnant or breast feeding
  • Other types of warts, ie. plantar
  • Currently participating in another clinical study
  • Chronic viral hepatitis B or C

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00117871


Locations
United States, Minnesota
Minnesota Clinical Study Center
Fridley, Minnesota, United States, 55432
Sponsors and Collaborators
Graceway Pharmaceuticals, LLC

ClinicalTrials.gov Identifier: NCT00117871     History of Changes
Other Study ID Numbers: 1515-RESI
First Posted: July 11, 2005    Key Record Dates
Last Update Posted: February 19, 2007
Last Verified: November 2006

Keywords provided by Graceway Pharmaceuticals, LLC:
Warts
Adults
Common Warts
Resiquimod

Additional relevant MeSH terms:
Warts
Papillomavirus Infections
DNA Virus Infections
Virus Diseases
Skin Diseases, Viral
Tumor Virus Infections
Skin Diseases, Infectious
Skin Diseases